These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31193791)

  • 21. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
    Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
    J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
    Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
    Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion.
    Liu Y; Zhang L; Ma Z; Tian L; Liu Y; Liu Y; Chen Q; Li Y; Ma E
    Free Radic Res; 2019 Jul; 53(7):758-767. PubMed ID: 31170853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer.
    Cao A; Ma P; Yang T; Lan Y; Yu S; Liu L; Sun Y; Liu Y
    Mol Pharm; 2019 Jun; 16(6):2502-2510. PubMed ID: 30998372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy.
    Xiang Y; Chen L; Zhou R; Huang Y
    Int J Pharm; 2019 Oct; 570():118668. PubMed ID: 31494237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition.
    Cheng F; Pan Q; Gao W; Pu Y; Luo K; He B
    ACS Appl Mater Interfaces; 2021 Jun; ():. PubMed ID: 34130450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
    Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
    Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel α
    Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
    J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
    Yeung TK; Hopewell JW; Simmonds RH; Seymour LW; Duncan R; Bellini O; Grandi M; Spreafico F; Strohalm J; Ulbrich K
    Cancer Chemother Pharmacol; 1991; 29(2):105-11. PubMed ID: 1760851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts.
    Li C; Xue HG; Feng LJ; Wang ML; Wang P; Gai XD
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4437-4445. PubMed ID: 29077148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Danshensu-Tetramethylpyrazine Conjugate DT-010 Overcomes Multidrug Resistance in Human Breast Cancer.
    Zhou X; Wang A; Wang L; Yin J; Wang L; Di L; Hoi MP; Shan L; Wu X; Wang Y
    Front Pharmacol; 2019; 10():722. PubMed ID: 31293428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.